Desulfovibrio

Almost everyone carries these bacteria. When labs use sensitive DNA methods, Desulfovibrio turns up in nearly every stool sample tested, healthy or sick. So the useful question on your report is rarely whether you have them. It's how much shows up, and whether that fits your symptoms and your earlier results.

The findings that matter are about quantity and pattern, not simple presence. Higher counts have been linked with diarrhea-predominant irritable bowel patterns, Parkinson's severity, and colorectal adenomas in some cohorts. None of those links proves cause and effect, and there is no validated cutoff separating a normal number from an abnormal one.

What the Test Actually Measures

This is a stool DNA test. PCR copies and counts a selected stretch of bacterial DNA. Most assays target the 16S ribosomal RNA gene, a bacterial barcode with enough variation to separate groups. Some research assays target dsrAB, a gene used by sulfate-reducing bacteria. Those are related but different readouts, so a 16S stool result should not be treated as a direct measure of sulfate-reduction capacity.

The assay is counting bacterial DNA copies or relative sequence abundance, depending on the platform. It is not measuring hydrogen sulfide. It is not measuring whether your gut lining is inflamed or damaged. Those are inferences, one step removed from what the machine reports.

The reason anyone cares about the count is what these bacteria do for a living. They use sulfate at the end of their energy chain and can feed on lactate, hydrogen gas, or sulfur-containing compounds such as taurine and cysteine. The waste product is hydrogen sulfide. At high enough concentrations, that gas can injure the cells lining the colon.

Why Your Number Might Be High or Low for Boring Reasons

Age moves this more than most people expect. Healthy infants and healthy older adults carry far more of these bacteria than healthy young adults in quantitative PCR work. Infant feeding shifts it too: formula-fed babies tend to carry higher levels than breast-fed babies, and counts rise after weaning.

Antibiotics can wipe them out. In hospitalized older adults, systemic antibiotic treatment reduced fecal Desulfovibrio counts and eliminated the organism entirely in nearly three of every ten patients. If you've been on antibiotics recently, a low result tells you about the antibiotics, not about your usual gut pattern.

Sampling matters too. Daily quantitative stool profiling found substantial day-to-day swings in how much of a given genus shows up between consecutive samples, though most genera still fluctuate around a personal baseline. That doesn't make the test useless. It means a single sample is a snapshot. A small controlled feeding study found that short-term high versus low sulfur amino acid intake did not shift Desulfovibrio relative abundance, so this marker doesn't seem to move quickly just because you changed sulfur-containing protein for a week or two.

Irritable Bowel, Specifically the Diarrhea Kind

This is the association with the best mechanistic fit. In people with diarrhea-predominant IBS, stool sequencing shows enrichment of hydrogen-sulfide-producing organisms including Desulfovibrio. Those people also breathe out more hydrogen sulfide on specialized triple-gas breath testing. Two independent measurements point at the same activity.

The mirror image is the constipation subtype, where methane-producing organisms dominate instead. That gives the gas pattern some explanatory value: sulfide-heavy profiles associate with faster transit, methane-heavy profiles with slower transit. If you have chronic diarrhea and your count runs high, the combination is worth taking to a gastroenterologist, particularly alongside a breath test that includes hydrogen sulfide. Even here, individual organism counts vary enormously between people, so no threshold has been established.

Colorectal Adenomas and Cancer

The evidence points in both directions. Several stool studies find Desulfovibrio enriched along the adenoma-to-carcinoma sequence, including in people with Lynch syndrome. Lynch syndrome sharply raises inherited colorectal cancer risk. In that cohort, the enrichment showed up in both stool and colon biopsy tissue in people who had adenomas at baseline.

Against that, the stool-only data are mixed. One culture-independent qPCR study found lower counts in people with colorectal cancer, about 10 times fewer gene copies per gram than in healthy young adults or people with prior polyps. Another qPCR study found no significant Desulfovibrio difference between colorectal cancer, upper gastrointestinal cancer, and healthy controls, while butyrate-producing bacteria were lower in colorectal cancer. Surgery, altered transit, and treatment can all change what ends up in stool.

A single bacterial count can mean different things at different points in a disease process. The same activity could be higher early, lower after surgery, and irrelevant in a healthy person with the same count. This is why machine-learning models built on stool signatures have only modest performance when asked to predict who has an adenoma.

The practical consequence is simple. A high count does not substitute for colonoscopy or a fecal immunochemical test, and a low count does not excuse you from them. If you're due for colorectal screening, get screened. Nothing on this report changes that.

Parkinson's Disease and Neurological Links

In a study of 20 people with Parkinson's disease and 20 controls, species-specific PCR detected known Desulfovibrio species more often in the Parkinson's group. A Desulfovibrio-linked hydrogenase gene also turned up more often in those samples. Quantitative levels were higher in Parkinson's, and higher levels tracked with more severe motor disease. That pattern is harder to dismiss than a simple yes-or-no difference, though it still does not prove cause.

The proposed mechanism involves hydrogen sulfide, lipopolysaccharide on bacterial outer membranes, and magnetite particles. Each has been proposed to push alpha-synuclein to clump. Alpha-synuclein is the protein that aggregates in Parkinson's. A 2025 stool sequencing and metabolomics study also found higher Desulfovibrio in Alzheimer's, Parkinson's, and ALS cohorts, alongside altered sulfur metabolism.

Read this carefully, because it's the finding most likely to be misused. These are cross-sectional studies: they photographed people who already had disease. Nobody has shown that carrying more of these bacteria precedes or causes Parkinson's, and gut changes in Parkinson's could follow from the slowed intestinal transit that the disease itself produces. A high count is not an early warning of Parkinson's and should not be treated as one.

Inflammatory Bowel Disease and Other Systemic Associations

Desulfovibrio piger, the dominant species in many human studies, was found in 55% of people with inflammatory bowel disease versus 12% of healthy individuals in a stool study using culture followed by species-specific PCR. That's a real gap. But when researchers went further and counted the bacteria living on rectal tissue, active ulcerative colitis and healthy control tissue carried similar loads. Presence differed; tissue burden did not.

Elevated abundance has also been reported in systemic sclerosis, in chronic kidney disease where it correlated with worse filtration and higher inflammatory markers, and in celiac disease with multiple autoimmune conditions. Going the other direction, one study of non-diabetic adults with overweight or obesity found Desulfovibrio was depleted in those with insulin resistance, not enriched.

These are observational and cross-sectional findings. The missing experiment is straightforward: lower this organism in a targeted way, keep the rest of the gut stable, and show that symptoms or inflammation improve. That hasn't been done.

Why One Reading Is Not Enough

The best reason to trend this marker is that a lone result is thin evidence. There is no reference range, so the useful comparison is your result against your earlier result, collected under similar conditions.

Two samples a few days apart can be more useful than one, because stool is uneven and low-abundance organisms can vary. A multi-day picture beats a single spot reading.

One caution on what a change means. Several interventions have been shown to move this number: vitamin C lowered relative abundance in a small randomized trial, antibiotics suppress it, and microbiota transfer therapy raised it. But no trial has shown that moving the number changes a clinical outcome. A falling count means the count fell. It does not yet mean you got healthier.

What to Do With an Out-of-Pattern Result

Start by asking what else is on the report, because this organism means almost nothing alone. Look for it alongside methane-producing organisms like Methanobrevibacter smithii: a sulfide-heavy, methane-light profile in someone with loose stools is a coherent pattern, while the reverse fits constipation. Fecal calprotectin tells you whether the gut is inflamed. The bacterial count does not.

If you have real gastrointestinal symptoms, a standard enteric pathogen panel comes first to rule out infection before anyone attributes symptoms to a commensal shift. Diarrhea plus high counts plus elevated breath hydrogen sulfide is a combination worth bringing to a gastroenterologist. A high count with no symptoms and normal calprotectin is a number to note and recheck, not a problem to treat.

The one thing not to do is treat a high count as an infection requiring antibiotics. These are normal residents of a normal gut. Eradicating them has never been shown to help anyone, and broad-spectrum antibiotics can damage the rest of the gut community.